
According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Supernus Pharmaceuticals is not utilizing their capital as effectively as possible. Supernus Pharmaceuticals reached earnings of $21.56 million and sales of $148.46 million in Q3.